Revenue and profit rose sharply year-over-year, led by strong sales of Lenvima, Leqembi, and Dayvigo, and supported by favorable currency effects. FY2026 guidance remains unchanged, with robust growth expected across all major segments.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.